Interpreting Key Trials

Angiotensin-receptor blockers in heart failure: Evidence from the CHARM trial

Author and Disclosure Information

ABSTRACTThe large Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial recently found that in patients with heart failure who were similar to those whom clinicians see in everyday practice, the angiotensin-receptor blocker candesartan was not only an acceptable alternative to angiotensin-converting enzyme (ACE) inhibitors, but also was beneficial when added to regimens that already included ACE inhibitors and beta-blockers. Candesartan was beneficial in heart failure patients with or without left ventricular systolic dysfunction.


Next Article:

What kind of physical examination does a young athlete need before participating in sports?

Related Articles